These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

115 related items for PubMed ID: 35122754

  • 21. Anlotinib Overcomes Multiple Drug Resistant Colorectal Cancer Cells via Inactivating PI3K/AKT Pathway.
    Lan W, Zhao J, Chen W, Shang H, Peng J, Lin J.
    Anticancer Agents Med Chem; 2021; 21(15):1987-1995. PubMed ID: 33438566
    [Abstract] [Full Text] [Related]

  • 22. PI3K/AKT pathway promotes keloid fibroblasts proliferation by enhancing glycolysis under hypoxia.
    Wang Q, Yang X, Ma J, Xie X, Sun Y, Chang X, Bi H, Xue H, Qin Z.
    Wound Repair Regen; 2023 Mar; 31(2):139-155. PubMed ID: 36571288
    [Abstract] [Full Text] [Related]

  • 23. Glycometabolic adaptation mediates the insensitivity of drug-resistant K562/ADM leukaemia cells to adriamycin via the AKT-mTOR/c-Myc signalling pathway.
    Zhang X, Ai Z, Chen J, Yi J, Liu Z, Zhao H, Wei H.
    Mol Med Rep; 2017 Apr; 15(4):1869-1876. PubMed ID: 28259993
    [Abstract] [Full Text] [Related]

  • 24. Shenmai Injection Supresses Glycolysis and Enhances Cisplatin Cytotoxicity in Cisplatin-Resistant A549/DDP Cells via the AKT-mTOR-c-Myc Signaling Pathway.
    Sun Y, Chen Y, Xu M, Liu C, Shang H, Wang C.
    Biomed Res Int; 2020 Apr; 2020():9243681. PubMed ID: 32685545
    [Abstract] [Full Text] [Related]

  • 25. Cancer Associated Fibroblast-Derived Hepatocyte Growth Factor Inhibits the Paclitaxel-Induced Apoptosis of Lung Cancer A549 Cells by Up-Regulating the PI3K/Akt and GRP78 Signaling on a Microfluidic Platform.
    Ying L, Zhu Z, Xu Z, He T, Li E, Guo Z, Liu F, Jiang C, Wang Q.
    PLoS One; 2015 Apr; 10(6):e0129593. PubMed ID: 26115510
    [Abstract] [Full Text] [Related]

  • 26. MAY, a novel tubulin inhibitor, induces cell apoptosis in A549 and A549/Taxol cells and inhibits epithelial-mesenchymal transition in A549/Taxol cells.
    Du J, Li J, Gao M, Guan Q, Liu T, Wu Y, Li Z, Zuo D, Zhang W, Wu Y.
    Chem Biol Interact; 2020 May 25; 323():109074. PubMed ID: 32217108
    [Abstract] [Full Text] [Related]

  • 27. INPP4B-mediated tumor resistance is associated with modulation of glucose metabolism via hexokinase 2 regulation in laryngeal cancer cells.
    Min JW, Kim KI, Kim HA, Kim EK, Noh WC, Jeon HB, Cho DH, Oh JS, Park IC, Hwang SG, Kim JS.
    Biochem Biophys Res Commun; 2013 Oct 11; 440(1):137-42. PubMed ID: 24051093
    [Abstract] [Full Text] [Related]

  • 28. Esomeprazole overcomes paclitaxel-resistance and enhances anticancer effects of paclitaxel by inducing autophagy in A549/Taxol cells.
    Bai Z, Ding N, Ge J, Wang Y, Wang L, Wu N, Wei Q, Xu S, Liu X, Zhou G.
    Cell Biol Int; 2021 Jan 11; 45(1):177-187. PubMed ID: 33049093
    [Abstract] [Full Text] [Related]

  • 29. ROS/PI3K/Akt and Wnt/β-catenin signalings activate HIF-1α-induced metabolic reprogramming to impart 5-fluorouracil resistance in colorectal cancer.
    Dong S, Liang S, Cheng Z, Zhang X, Luo L, Li L, Zhang W, Li S, Xu Q, Zhong M, Zhu J, Zhang G, Hu S.
    J Exp Clin Cancer Res; 2022 Jan 08; 41(1):15. PubMed ID: 34998404
    [Abstract] [Full Text] [Related]

  • 30. Huaier shows anti-cancer activities by inhibition of cell growth, migration and energy metabolism in lung cancer through PI3K/AKT/HIF-1α pathway.
    Liu X, Liu L, Chen K, Sun L, Li W, Zhang S.
    J Cell Mol Med; 2021 Feb 08; 25(4):2228-2237. PubMed ID: 33377619
    [Abstract] [Full Text] [Related]

  • 31. PI3K/Akt signaling mediated Hexokinase-2 expression inhibits cell apoptosis and promotes tumor growth in pediatric osteosarcoma.
    Zhuo B, Li Y, Li Z, Qin H, Sun Q, Zhang F, Shen Y, Shi Y, Wang R.
    Biochem Biophys Res Commun; 2015 Aug 21; 464(2):401-6. PubMed ID: 26116768
    [Abstract] [Full Text] [Related]

  • 32. Tumor-targeted nano-assemblies for energy-blocking cocktail therapy in cancer.
    Chen M, Liu Y, Li Y, Liu X.
    Acta Biomater; 2024 Aug 21; 184():368-382. PubMed ID: 38908417
    [Abstract] [Full Text] [Related]

  • 33. Everolimus regulates the activity of gemcitabine-resistant pancreatic cancer cells by targeting the Warburg effect via PI3K/AKT/mTOR signaling.
    Cui J, Guo Y, Wu H, Xiong J, Peng T.
    Mol Med; 2021 Apr 13; 27(1):38. PubMed ID: 33849427
    [Abstract] [Full Text] [Related]

  • 34. ABT737 reverses cisplatin resistance by targeting glucose metabolism of human ovarian cancer cells.
    Xu Y, Gao W, Zhang Y, Wu S, Liu Y, Deng X, Xie L, Yang J, Yu H, Su J, Sun L.
    Int J Oncol; 2018 Sep 13; 53(3):1055-1068. PubMed ID: 30015875
    [Abstract] [Full Text] [Related]

  • 35. Anticancer efficacy of a nitric oxide-modified derivative of bifendate against multidrug-resistant cancer cells.
    Ren Z, Gu X, Lu B, Chen Y, Chen G, Feng J, Lin J, Zhang Y, Peng H.
    J Cell Mol Med; 2016 Jun 13; 20(6):1095-105. PubMed ID: 26864945
    [Abstract] [Full Text] [Related]

  • 36. Glycolytic inhibitor 2-deoxy-d-glucose suppresses cell proliferation and enhances methylprednisolone sensitivity in non-Hodgkin lymphoma cells through down-regulation of HIF-1α and c-MYC.
    Pang YY, Wang T, Chen FY, Wu YL, Shao X, Xiao F, Huang HH, Zhong H, Zhong JH.
    Leuk Lymphoma; 2015 Jun 13; 56(6):1821-30. PubMed ID: 25219592
    [Abstract] [Full Text] [Related]

  • 37. Survivin suppression heightens BZML-induced mitotic catastrophe to overcome multidrug resistance by removing therapy-induced senescent A549/Taxol cells.
    Bai Z, Zhou Y, Ye X, Li Y, Peng Y, Guan Q, Zhang W, Ma L.
    Biochim Biophys Acta Mol Cell Res; 2022 Feb 13; 1869(2):119174. PubMed ID: 34808206
    [Abstract] [Full Text] [Related]

  • 38. Overcoming cisplatin resistance of ovarian cancer cells by targeting HIF-1-regulated cancer metabolism.
    Ai Z, Lu Y, Qiu S, Fan Z.
    Cancer Lett; 2016 Apr 01; 373(1):36-44. PubMed ID: 26801746
    [Abstract] [Full Text] [Related]

  • 39. Mitochondrial DNA content reduction induces aerobic glycolysis and reversible resistance to drug-induced apoptosis in SW480 colorectal cancer cells.
    Mou JJ, Peng J, Shi YY, Li N, Wang Y, Ke Y, Zhou YF, Zhou FX.
    Biomed Pharmacother; 2018 Jul 01; 103():729-737. PubMed ID: 29684851
    [Abstract] [Full Text] [Related]

  • 40. Structure-Based Drug Design and Synthesis of Novel N-Aryl-2,4-bithiazole-2-amine CYP1B1-Selective Inhibitors in Overcoming Taxol Resistance in A549 Cells.
    Mao J, Wang D, Xu P, Wang Y, Zhang H, Wang S, Xu F, Wang J, Zhang F.
    J Med Chem; 2022 Dec 22; 65(24):16451-16480. PubMed ID: 36512763
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.